IRD ▲ +3.3% - Opus Genetics, Inc.
$IRD - Opus Genetics Completes Dosing in Cohort 2 of Phase 1/2 Clinical Trial of OPGx-BEST1 Gene Therapy for Inherited Retinal Diseases
05-NOV-2026 07:00 AM ET
Share this post
More filings for $IRD
IRD ▼ -0.5% - Opus Genetics, Inc.Nov 3, 2026IRD ▼ -2.4% - Opus Genetics, Inc.Oct 29, 2026IRD - Opus Genetics, Inc. - SEC Filing Update (27-OCT-2026) | ThinkSabio - Stocks SimplifiedOct 27, 2026IRD ▲ +2.0% - Opus Genetics, Inc.Oct 21, 2026IRD ▼ -4.9% - Opus Genetics, Inc.Oct 16, 2026IRD ▼ -1.2% - Opus Genetics, Inc.Oct 15, 2026
View full $IRD filing history →💬 Comments
Loading comments…
Leave a comment